Vertex Pharmaceuticals Incorporated (BIT:1VRTX)

Market Cap	101.47B
Revenue (ttm)	10.27B
Net Income (ttm)	-914.93M
Shares Out	n/a
EPS (ttm)	-3.55
PE Ratio	n/a
Forward PE	23.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52
Average Volume	5
Open	379.45
Previous Close	382.45
Day's Range	369.65 - 391.70
52-Week Range	369.50 - 486.10
Beta	n/a
RSI	34.90
Earnings Date	May 5, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1VRTX

Financial Performance

Financial numbers in USD